https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=11403
No pharmaceutical opinion available for this interaction.
St. John's Wort may induce the metabolism (UGT 1A1 and CYP3A) and decrease the plasma concentration of Dolutegravir.
Possible decrease of clinical efficacy.
Tivicay : An increased dose of dolutegravir to 50 mg BID is recommended.
Triumeq or Dovato : Administer an additional dose of 50 mg dolutegravir 12 hours after Triumeq or Dovato.
Monitor for clinical efficacy.
Avoid combination in patients with resistance to integrase inhibitors.
Juluca : Concomitant administration contraindicated.
–
–
–
–
–
Dolutegravir plasma level
CD4+
Viral load HIV
–
Co-administration has not been studied. However, St. John's Wort is a potent inducer of CYP3A4 such as carbamazepine, so we can expect similar reductions as seen in the interaction between carbamazepine and dolutegravir. See dolutegravir and carbamazepine.